India, June 15 -- Redcare Pharmacy N.V. (SAE1.F,RDC.DE) Monday raised its full-year 2026 guidance after reporting stronger-than-expected trading during the first two months of the second quarter, driven by accelerating growth in both prescription (Rx) and non-prescription (non-Rx) sales.
The online pharmacy operator said group revenue increased 20% year-over-year quarter-to-date, with growth accelerating compared with the first quarter of 2026. The DACH segment, comprising Germany, Austria and Switzerland, posted 21% revenue growth, supported by stronger non-Rx sales and continued momentum in prescription medicines.
In Germany, non-Rx growth accelerated to 14% year-over-year during the first two months of the quarter, compared with 9% gro...